Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies

Authors:

Abstract
3139 Background UCN-01, 7-hydroxystaurosporine, is a cell cycle modulator that abrogates the G2 checkpoint induced by DNA damaging agents, such as irinotecan, leading cells to apoptosis. We performed a Phase I study combining UCN-01 with irinotecan to define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in resistant solid tumor malignancies and evaluate pharmacokinetics (PK) and pharmacodynamics (PD) of the combination. Methods Patients were treated with irinotecan on days 1, 8, 15, 22 followed by UCN-01 on days 2 and 23 every 42 days. Dose escalation proceeded as follows: Blood samples were collected for pharmacokinetics of irinotecan, SN-38, SN-38 glucuronide and aminopentanocarboxylic acid (APC), and total and unbound UCN-01. Polymorphonuclear cells and normal rectal tissue were collected for cell cycle profiling and phosphorylation of Chk1, Cdc25c, and Cdc2. Results Eleven patients with resistant solid tumor malignancies were treated. In dose level 3, a grade 3 ANC with a >14 day treatment delay was dose-limiting. We are presently expanding this level to 6 patients. In cycle 1, dose level 3, a grade 3 malaise/fatigue occurred. No grade 4 toxicity occurred. PK analyses demonstrated the area under the curve (AUC) of irinotecan, SN-38, SN-38G, and APC was not influenced by UCN-01 administration through dose level 3. In the first two dose levels, there was no significant increase in the AUC of UCN-01. PD samples were collected and analyses will be performed at completion of patient enrollment. Response data on 11 patients reveal 6 with stable disease (range 5–26 weeks) and 5 with progressive disease. Conclusions The combination therapy of UCN-01 and irinotecan at dose level 3 is well-tolerated. At this time, there is no evidence of a PK interaction between these agents. Patient accrual continues at dose level 3. No significant financial relationships to disclose.